Type II Bare Lymphocyte Syndrome: Role of Peripheral Blood Flow Cytometry and Utility of Stem Cell Transplant in Treatment

Major histocompatibility complex class II (MHCII) deficiency is a rare autosomal recessive immunodeficiency disorder characterized by lack of expression of MHCII molecules, causing defective CD4+ lymphocyte function and an impaired immune response. Clinical manifestations include susceptibility to severe bacterial, viral, and fungal infections which can lead to failure to thrive and childhood death. The only definitive treatment to date is allogeneic stem cell transplantation. Here, we share our experience of 2 patients who presented with MHCII deficiency. We will discuss the role of diagnostic modalities and stem cell transplantation.

[1]  J. Puck,et al.  Immune deficiencies, infection, and systemic immune disordersNewborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: Results of the first 2 years , 2013 .

[2]  W. Friedrich,et al.  Alternative donor SCT for the treatment of MHC Class II deficiency , 2013, Bone Marrow Transplantation.

[3]  M. Barbouche,et al.  Clinical, Immunological and Genetic Findings of a Large Tunisian Series of Major Histocompatibility Complex Class II Deficiency Patients , 2013, Journal of Clinical Immunology.

[4]  R. Djidjik,et al.  Clinical, immunological and genetic features in eleven Algerian patients with major histocompatibility complex class II expression deficiency , 2012, Allergy, Asthma & Clinical Immunology.

[5]  A. Fischer,et al.  Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation: a survey of 35 patients. , 2011, Blood.

[6]  U. Göbel,et al.  MHC class II deficiency cured by unrelated mismatched umbilical cord blood transplantation: Case report and review of 68 cases in the literature , 2011, Pediatric transplantation.

[7]  A. Al-ghonaium,et al.  Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  A. Fischer,et al.  Human leucocyte antigen‐identical haematopoietic stem cell transplantation in major histocompatiblity complex class II immunodeficiency: reduced survival correlates with an increased incidence of acute graft‐versus‐host disease and pre‐existing viral infections , 2006, British journal of haematology.

[9]  W. Reith,et al.  MHC class II deficiency: a disease of gene regulation. , 2001, Medicine.

[10]  W. Reith,et al.  Lessons from the bare lymphocyte syndrome: molecular mechanisms regulating MHC class II expression , 2000, Immunological reviews.

[11]  P. Veys,et al.  Clinical course of patients with major histocompatibility complex class II deficiency , 2000, Archives of disease in childhood.

[12]  R. Elhasid,et al.  Major histocompatibility complex class II deficiency: a clinical review. , 1996, Blood reviews.

[13]  R. Jaenisch,et al.  Mice lacking major histocompatibility complex class I and class II molecules. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[14]  W. Reith,et al.  The bare lymphocyte syndrome and the regulation of MHC expression. , 2001, Annual review of immunology.

[15]  L. Glimcher,et al.  Immune responses in MHC class II-deficient mice. , 1995, Annual Review of Immunology.